Loading...
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
BACKGROUND: Despite preventive vaccines for oncogenic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can lead to long-term reproductive morbidity. We assessed whether VGX-3100, synthetic plasmids targeting HPV-16 and HPV-18...
Na minha lista:
| Udgivet i: | Lancet |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4888059/ https://ncbi.nlm.nih.gov/pubmed/26386540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00239-1 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|